Subscriber Content Preview | Request a free trialSearch  


Battle rages over whether an old drug can be new again

Takeover candidate United Therapeutics fights Sandoz over patents for treating a rare disorder. Continue reading

Stryker and Smith & Nephew are the stars to watch in medtech's 2015 merger dance

After a robust year of mega-deals In 2014, mid-size device makers are expected to seek partners, fueling even further consolidation. Continue reading

Valeant follows failed Allergan bid with $14.5B Salix acquisition

Following last year's failed attempt to purchase Allergan, the Canadian pharmaceutical giant continues its acquisition strategy with its latest deal. Continue reading

Activist Investing: Impact on M&A

Armed with more than $100 billion in capital and a tenacity to match, activist money managers have become an investment juggernaut. Continue reading

From one CEO to another: Activism with a lighter touch

Two Wall Street veterans recruit a team of corporate chieftains at Hudson Executive Capital. The firm won't engage in proxy fights; instead, it will take a collaborative approach to strategic dealmaking. Continue reading

Rite Aid sees wider margins in $2B Envision deal

The cash and stock acquisition of TPG Capital-backed pharmacy-benefit manager follows rival CVS' successful purchase of Caremark. Continue reading

Hospitals respond to Medicare worries with a shopping spree

Uncertainty over reimbursement levels and increased regulatory burdens are putting pressure on margins. So the big operators have decided that the best way to protect their bottom lines is to get even bigger. Continue reading

Reverse merger market shrank in fourth quarter

Despite the decline in deals, reverse merger companies raised more capital. Continue reading

Skilled Healthcare hunts for small deals after merger

After Genesis Healthcare deal closes, Skilled will focus on short stay facility acquisitions. Continue reading

Five developments to watch as activism gains steam

With the economy slowly recovering in 2014, activist investors had a field day. So did advisers to companies fighting off their most vocal investors, or those concerned that an activist might put in an appearance. Continue reading

Mylan ex-CEO, Glass Lewis debate proxy adviser power

Glass Lewis to provide background info to 250 companies before distributing recommendations. Continue reading

Johnson & Johnson makes $835M deal with Isis

By investing in Isis Pharmaceuticals, the pharmaceutical giant, through its Janssen unit, expands its commitment to antisense drug treatment programs. Continue reading

Meet the journalists

Pfizer adds Hospira in $17B acquisition

The buyer gets growing injectables and biosimilars businesses. Video

More Healthcare video

The Deal's Webcast Series

If you have not had the chance to enjoy our Webcast Series, now is the time. Join these free 60-minute discussions and get a handle on the latest strategies and tactics in private equity, cross-border and middle market dealmaking and more.

Industry Events

View information on all upcoming industry events which The Deal representatives are participating in.

The Deal Economy Event

The Deal’s senior journalists host the industry's leading M&A forecasting event, an invitation-only gathering of influential members of the deal community discussing the outlook for dealmaking in the coming year.

The Deal on Twitter

Follow @TheDealNewsroom for the latest news across mergers and acquisitions, auctions, financings, restructurings and more!